Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: An open-label, randomised, phase 3 trial Journal Article
| Authors: | Cella, D.; Motzer, R. J.; Suarez, C.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J. F.; Simsek, B.; Zhang, J.; Ivanescu, C.; Apolo, A. B.; Choueiri, T. K. |
| Article Title: | Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: An open-label, randomised, phase 3 trial |
| Journal Title: | Lancet Oncology |
| Volume: | 23 |
| Issue: | 2 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2022-02-01 |
| Start Page: | 292 |
| End Page: | 303 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(21)00693-8 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 35032437 |
| PMCID: | PMC9479564 |
| DOI/URL: | |
| Notes: | Accession Number: 154950394 -- Entry Date: In Process -- Revision Date: 20220201 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 100957246. -- Source: Cinahl |
